762 / 1708
Group III Orbital RMS
Protocol
Dose
(Gy)
Chemotherapy Timing of
RT (week)
5-year local
failure rate
(%)
5-year
failure-free
survival (%)
IRS-III
(n = 71)
41.4 –
50.4
VA
2 or 6
16
79
IRS-IV
(n = 49)
50.4-
59.4
VAC(26.4g/m
2
)/
VAI/VIE
9
2
94
D9602
45 VA
13
14
86
ARST0331
45 VAC(4.8g/m
2
)
13
13
87
CR (n = 15)
0
100
PR/SD (n =38)
16
84
Ermoian RP et al. Pediatr Blood Cancer 2017; 64:e26540